Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 19;7(1):13-20.
doi: 10.1159/000515959. eCollection 2022 Jan.

Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?

Affiliations
Review

Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?

Beatriz Yuki Maruyama et al. Inflamm Intest Dis. .

Abstract

Background: Despite reductions in surgical rates that have been observed with earlier use of biological therapy, surgery still constitutes an important tool in the therapeutic armamentarium in Crohn's disease (CD), particularly in patients with stenotic and penetrating phenotypes. In these scenarios, early surgical intervention is recommended, as bowel damage is present and irreversible, leading to lower efficacy with biologics.

Summary: The concept of early surgery in CD supposes the possible advantages of better surgical outcomes in luminal CD after initial resection. Optimal timing of surgical intervention is associated with better postoperative outcomes, whilst delays can lead to more technically difficult and extensive procedures, which may result in an increase in postoperative complication rates and higher rates of stoma formation. Furthermore, data from the LIR!C trial have demonstrated that early surgery in luminal localized inflammatory ileocecal CD is an adequate alternative to medical therapy, with lower societal costs in the long term. In this review, we discuss the position of early resection in ileocecal CD by critically reviewing available data, describing the ideal patients to be considered for early surgery, and weighing the potential advantages and disadvantages of an early surgery paradigm.

Key messages: While early surgery may not be the right choice for every patient, the ultimate decision regarding whether surgical or medical therapy should come first in the treatment paradigm must be individualized for each patient based on the disease characteristics, phenotype, risk factors, and personal preference. This highlights the importance of the multidisciplinary team, which remains a key pillar in deciding the overall management plan for patients with CD.

Keywords: Crohn's disease; Laparoscopy; Surgery.

PubMed Disclaimer

Conflict of interest statement

Christopher Ma has received consulting fees from Robarts Clinical Trials. Remo Panaccione has received consulting and speaker fees from AbbVie, Allergan, Celgene, Eli Lily, Ferring, Gilead, Janssen, Shire, and Takeda; served as a Scientific Advisory Board member for AbbVie, Allergan, Celgene, Eli Lily, Janssen, and Takeda; and received research grants from AbbVie, Janssen, and Takeda. Paulo Kotze has received consulting and speaker fees from AbbVie, Janssen, Pfizer, Takeda, and UCB. Beatriz Maruyama has no conflicts of interest.

Comment in

Similar articles

Cited by

References

    1. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nat Rev Dis Primers. 2020;6((1)):22. - PubMed
    1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adali­mumab for maintenance of clinical response and remission in patients with Crohn's disease the CHARM trial. Gastroenterology. 2007;132((1)):52–65. - PubMed
    1. Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn's disease [CALM] a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;6736((17)):1–11. - PubMed
    1. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375((20)):1946–60. - PubMed
    1. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease [REACT] a cluster randomised controlled trial. Lancet. 2015;386((10006)):1825–34. - PubMed